Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review

The use of Edaravone, given orally, for the treatment of amyotrophic lateral sclerosis (ALS) was officially approved by the Federal Drug Association (FDA) in 2017. ALS is a rare and progressive degenerative disease that worsens over time. It attacks and destroys the nerve cells that control voluntar...

Descripción completa

Detalles Bibliográficos
Autores principales: Neupane, Purushottam, Thada, Pawan Kumar, Singh, Pramod, Faisal, Abdul Rafae, Rai, Niraj, Poudel, Prabhat, Waleed, Madeeha Subhan, Quinonez, Jonathan, Ruxmohan, Samir, Jain, Esha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922523/
https://www.ncbi.nlm.nih.gov/pubmed/36788871
http://dx.doi.org/10.7759/cureus.33746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922523/
https://www.ncbi.nlm.nih.gov/pubmed/36788871
http://dx.doi.org/10.7759/cureus.33746

Ejemplares similares